SB-773812

SB-773812 is an investigational small molecule drug developed for the treatment of schizophrenia. It acts primarily as an antagonist at several serotonin receptors, including 5-hydroxytryptamine (serotonin) receptor 2A (5-HT2A), 5-hydroxytryptamine receptor 2C (5-HT2C), and 5-hydroxytryptamine receptor 6 (5-HT6). The drug also exhibits moderate antagonism at dopamine D2 receptors. Clinical studies have demonstrated that SB-773812 penetrates the brain and binds to its target receptors in humans, with high occupancy of the 5-HT2A receptor and moderate occupancy of D2 receptors. The compound was evaluated in multiple phase II clinical trials for efficacy and safety in adults with schizophrenia but has not been approved or marketed[1][4][6].